Seeking Alpha

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

Advances Amgen (AMGN)'s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- ...
The American Journal of Managed Care

Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases

After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter ...
Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
Morningstar

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA1 First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s ...
Monthly Prescribing Reference

Ready-To-Use, Low IgA Gammagard Liquid ERC Approved for Primary Immunodeficiency

Commercialization of Gammagard Liquid ERC is expected to begin in 2026. The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a ...